Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive Tumors

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2014 by Memorial Sloan Kettering Cancer Center.
Band of Parents
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center. Identifier:
First received: August 17, 2011
Last updated: November 26, 2014
Last verified: November 2014

The purpose of this study is to find out if "humanized 3F8" (Hu3F8) is safe for treating neuroblastoma and other cancers. A phase 1 study means the investigators are trying to find out what side effects happen when higher and higher doses of a drug are used.

The investigators want to find out what effects, good and/or bad, Hu3F8 has on cancer. The amount of Hu3F8 that patients gets will depend on when they start treatment on this study. The investigators also want to find out more about how Hu3F8 works and how effective it is in attacking the disease. Hu3F8 is an experimental drug, which means it has not yet been approved by the FDA for the treatment of this disease.

Condition Intervention Phase
Biological: Humanized 3F8 Monoclonal Antibody (Hu3F8)
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase I Study of Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive Tumors

Resource links provided by NLM:

Further study details as provided by Memorial Sloan Kettering Cancer Center.:

Primary Outcome Measures:
  • maximum tolerated dosage (MTD) [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
    At least 3 patients will be studied at each dosage level and dose escalations will only be carried out if 0/3 or < or = to 1/6 patients have dose-limiting toxicity (DLT). At least six patients will be studied at the maximum tolerated dosage (MTD).

Secondary Outcome Measures:
  • pharmacokinetics of hu3F8 [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    Pharmacokinetics will be measured by serial blood sampling following the iv doses of hu3F8 during cycle 1. Serum hu3F8 will be measured at the following times after infusion of the first hu3F8 infusion during the first cycle: 0, 5 min, 3h, 6-8h, 24h, 48h, 72h, 96, 120h 168h, 216h and 264 h and will also include peak hu3F8 level after infusion for each of the two hu3F8 injections during the first cycle. Peak hu3F8 level at 5 minutes after hu3F8 infusion on days 3 and 5. Pre-treatment and at 5 min after infusion will also be measured for all hu3F8 infusions during all other cycles.

  • To assess activity of hu3F8 against NB and other GD2-positive tumors. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    For neuroblastoma, anti-tumor activity will be measured by INRC.61 For other solid tumors, the response and progression will be evaluated in this study using the Response Evaluation Criteria in Solid Tumors (RECIST) Committee, version 1.1.62

  • To quantitate pain during hu3F8 treatment [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    As patient's pain will be assessed with a numerical score of 1 to 10 over the course of the treatment, a curve of pain intensity over time can be generated for each patient.

Estimated Enrollment: 72
Study Start Date: August 2011
Estimated Study Completion Date: August 2015
Estimated Primary Completion Date: August 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Humanized 3F8 Monoclonal Antibody (Hu3F8)
This phase I single arm trial assesses the toxicity of escalating doses of hu3F8.
Biological: Humanized 3F8 Monoclonal Antibody (Hu3F8)
Pts can be treated on 2 different schedules: Pts following a 2 doses/cycle schedule (pts who were enrolled & started treatment prior to A(8)), 1 cycle has 2 days of IV hu3F8 tx, given approximately 7 days apart. Pts following a 3 doses/cycle schedule, 1 cycle has 3 days of IV hu3F8 tx, given on days 1, 3 & 5. Cycles are 21 days & can be repeated up to a total of 12 cycles. Evaluations before, during & after tx are summarized in table. In addition, to further study the side effect of pain, pts will be asked to assess their pain on the days of tx with hu3F8 at 3 different time points: (a) prior to commencement of hu3F8, (b) at least 1 during the acute pain episode when rescue pain medication doses are usually required & (c) prior to discharge from the Pediatric Day Hospital. Pts who complete the 12 cycles of tx with no disease progression & if clinically indicated are eligible to receive additional cycles of tx for up to 2 years from the start of tx to a maximum of 20 cycles.


Ages Eligible for Study:   2 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients must have either (1) a diagnosis of NB as defined by international criteria,56 i.e., histopathology (confirmed by the MSKCC Department of Pathology) or BM metastases plus high urine catecholamine levels, or (2) a metastatic tumor that is GD2-positive by immunostaining with m3F8.
  • Patients must have either (1) refractory or relapsed high-risk NB (including MYCN-amplified stage 3/4/4S and MYCN-nonamplified stage 4 in patients greater than 18 months of age) resistant to standard therapy, or (2) refractory or relapsed GD2-positive tumor.
  • Patients must be older than 1 year of age.
  • Prior treatment with murine 3F8 is allowed. Patients with prior m3F8 or ch14.18 treatment must have HAHA antibody titer less than the upper limit of normal [defined as mean + 3*SD of normal volunteers].
  • Negative serum pregnancy test in women of childbearing potential.
  • Women of child-bearing potential must be willing to practice an effective method of birth control while on treatment
  • Signed informed consent indicating awareness of the investigational nature of this program.

Exclusion Criteria:

  • Existing major organ dysfunction > grade 2, with the exception of hearing loss and myelosuppression defined as suppression of all types of WBCs, RBCs and platelets). However, the following parameters must be met: white blood cell count ≥1000/ul, absolute (neutrophil count >500/ul absolute lymphocyte count ≥500/ul and platelet count > or = to 25,000/ul
  • Active life-threatening infection.
  • Pregnant women or women who are breast-feeding.
  • Inability to comply with protocol requirements.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01419834

Contact: Ellen Basu, MD, PhD 212-639-5204
Contact: Nai-Kong Cheung, MD, PhD 646-888-2313

United States, New York
Memorial Sloan Kettering Cancer Center Recruiting
New York, New York, United States, 10065
Contact: Ellen Basu, MD, PhD    212-639-5204      
Contact: Nai-Kong Cheung, MD, PhD    646-888-2313      
Principal Investigator: Ellen Basu, MD, PhD         
Sponsors and Collaborators
Memorial Sloan Kettering Cancer Center.
Band of Parents
Principal Investigator: Ellen Basu, MD,PhD Memorial Sloan Kettering Cancer Center.
  More Information

Additional Information:
No publications provided

Responsible Party: Memorial Sloan Kettering Cancer Center. Identifier: NCT01419834     History of Changes
Other Study ID Numbers: 11-009
Study First Received: August 17, 2011
Last Updated: November 26, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Memorial Sloan Kettering Cancer Center.:

Additional relevant MeSH terms:
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neuroectodermal Tumors, Primitive
Neuroectodermal Tumors, Primitive, Peripheral
Antibodies, Monoclonal
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs processed this record on March 30, 2015